News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,306 Results
Type
Article (13588)
Company Profile (110)
Press Release (247608)
Section
Business (87957)
Career Advice (462)
Deals (15327)
Drug Delivery (64)
Drug Development (36532)
Employer Resources (49)
FDA (6259)
Job Trends (6185)
News (150040)
Policy (14008)
Tag
Academia (435)
Alliances (23098)
Alzheimer's disease (352)
Approvals (6254)
Artificial intelligence (61)
Bankruptcy (143)
Best Places to Work (4328)
Biotechnology (44)
Breast cancer (42)
Cancer (315)
Career advice (405)
Cell therapy (44)
Clinical research (30408)
Collaboration (155)
Compensation (62)
COVID-19 (747)
C-suite (52)
Data (346)
Diabetes (53)
Diagnostics (1236)
Drug pricing (57)
Earnings (31569)
Employer resources (43)
Events (36747)
Executive appointments (173)
FDA (6440)
Funding (108)
Gene therapy (59)
GLP-1 (293)
Government (1267)
Healthcare (3522)
Infectious disease (765)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5821)
Job creations (2050)
Job search strategy (372)
Layoffs (167)
Legal (3411)
Lung cancer (46)
Manufacturing (99)
Medical device (1261)
Medtech (1263)
Mergers & acquisitions (9542)
Metabolic disorders (168)
Neuroscience (450)
NextGen Class of 2024 (1580)
Non-profit (590)
Northern California (435)
Obesity (101)
Opinion (109)
Patents (53)
People (28463)
Pharmaceutical (64)
Phase I (7907)
Phase II (12857)
Phase III (11555)
Pipeline (184)
Policy (45)
Postmarket research (1399)
Preclinical (3166)
Radiopharmaceuticals (116)
Rare diseases (90)
Real estate (2629)
Regulatory (9825)
Research institute (563)
Resumes & cover letters (55)
Southern California (436)
Startups (1625)
United States (4301)
Vaccines (112)
Weight loss (78)
Date
Last 7 days (229)
Last 30 days (1150)
Last 365 days (12727)
2024 (11653)
2023 (14247)
2022 (19558)
2021 (20071)
2020 (19035)
2019 (14886)
2018 (11714)
2017 (13889)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (42)
Asia (19798)
Australia (2559)
California (1012)
Canada (605)
China (113)
Colorado (43)
Connecticut (42)
Europe (38794)
Florida (153)
Illinois (111)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (155)
Massachusetts (883)
Minnesota (57)
New Jersey (426)
New York (281)
North Carolina (278)
Northern California (435)
Pennsylvania (288)
South America (498)
Southern California (436)
Texas (141)
Virginia (41)
Washington State (71)
261,306 Results for "asieris pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals
ReviR Therapeutics and Asieris Pharmaceuticals, a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases, announced a milestone was reached today in their ongoing collaboration.
June 17, 2024
·
4 min read
Business
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women’s Health Business Unit, Accelerating Strategic Expansion
Asieris Pharmaceuticals has announced its set-up of the Women’s Health Business Unit for commercialization.
January 8, 2024
·
6 min read
Drug Development
Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams
Asieris Pharmaceuticals released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization.
April 17, 2024
·
9 min read
Press Releases
Asieris Pharmaceuticals Releases 2024 Semi-Annual Report, Highlighting Steady Progress in Launching Blockbuster Product for Precancerous Cervical Lesions and Continued Strengthening of Commercial Revenue Generation Capabilities
August 28, 2024
·
7 min read
Drug Development
Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.
March 18, 2024
·
5 min read
Drug Development
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.
December 24, 2023
·
2 min read
Policy
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals communicated that the National Medical Products Administration accepted the new drug application for Hexvix® in China.
November 29, 2023
·
5 min read
Drug Development
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU
Asieris Pharmaceuticals announced the release of Phase III clinical trial data and real-world study data for APL-1706, a bladder cancer diagnosis and management drug, at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium in the form of a poster presentation.
January 29, 2024
·
3 min read
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
Asieris Pharmaceuticals announced the first-time release of interim analysis data for the Phase II clinical trial of oral APL-1202 in combination with the PD-1 inhibitor tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer.
January 29, 2024
·
4 min read
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
Asieris Pharmaceuticals released its 2023 Semi-Annual Report that highlights the accelerated progress in clinical trials, aiming to address the field’s highly unmet diagnostic and therapeutic needs.
August 22, 2023
·
9 min read
1 of 26,131
Next
